Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Hrzenjak, A; Reicher, H; Wintersperger, A; Steinecker-Frohnwieser, B; Sedlmayr, P; Schmidt, H; Nakamura, T; Malle, E; Sattler, W.
Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate.
CELL MOL LIFE SCI. 2004; 61(12): 1520-1531.
Doi: 10.1007/s00018-004-4101-4
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Hrzenjak Andelko
- Sattler Wolfgang
- Co-authors Med Uni Graz
- Hinteregger Helga
- Malle Ernst
- Schmidt Helena
- Sedlmayr Peter
- Steinecker-Frohnwieser Bibiane
- Wintersperger Andrea
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Alpha-tocopheryl-succinate (alphaTS) is a synthetic, anti-neoplastic derivative of alpha-tocopherol. Here we studied the effects of free and high-density lipoprotein subclass 3 (HDL3)-associated alphaTS on the growth of human (A549) and mouse Lewis (LL2) lung carcinoma cells. Both free and HDL3-associated alphaTS inhibited A549 growth in a time- and concentration-dependent manner. Treatment of A549 cells with alphaTS-enriched HDL3 led to DNA fragmentation and a time-dependent decrease in immunoreactivity of poly(ADP-ribose)polymerase. Uptake experiments revealed a high capacity for selective alphaTS uptake in excess of holoparticle endocytosis. Overexpression of scavenger receptor class B, type I (SR-BI), the prime receptor mediating selective lipid uptake, in A549 cells resulted in significantly increased selective alphaTS uptake, a finding associated with complete cellular growth arrest. The present in vitro findings were verified in an in vivo model: tumor inoculation in C57BL6 was performed with either wild-type, beta-galactosidase- or SR-BI-overexpressing LL2 cells. After tumor inoculation, the animals received six consecutive intravenous injections of alphaTS. This experimental setup resulted in significantly reduced tumor burden in animals that were inoculated with SR-BI-overexpressing LL2 cells but not in animals inoculated with wild-type or beta-galactocidase-transfected cells. Based on our in vitro and in vivo findings, we propose that SR-BI could provide a novel route for HDL3-mediated drug delivery of anti-neoplastic drugs.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenoviridae - genetics
- Animals - genetics
- Antigens, CD36 - genetics
- Carcinoma - drug therapy
- Cell Division - drug therapy
- Cell Line, Tumor - drug therapy
- Centrifugation, Density Gradient - drug therapy
- DNA Fragmentation - drug therapy
- Dose-Response Relationship, Drug - drug therapy
- Endocytosis - drug therapy
- Humans - drug therapy
- Hydrolysis - drug therapy
- Immunohistochemistry - drug therapy
- Lipoproteins, HDL - pharmacology
- Lung Neoplasms - drug therapy
- Mice - drug therapy
- Mice, Inbred C57BL - drug therapy
- Nucleosomes - metabolism
- Poly(ADP-ribose) Polymerases - metabolism
- Receptors, Immunologic - metabolism
- Receptors, Scavenger - metabolism
- Scavenger Receptors, Class B - metabolism
- Time Factors - metabolism
- Transfection - metabolism
- Vitamin E - analogs and derivatives
- beta-Galactosidase - metabolism
- Find related publications in this database (Keywords)
- HDL3
- vitamin E-succinate
- A549 cells
- LL2 cells
- SR-BI